In a similar way, studies are Temsirolimus msds needed to understand why most sedatives exacerbate disordered breathing during sleep, and to design countermeasures, or even drugs preventing, sleep apnea. As recently stressed by Mignot et al,13 the rapid growth of basic and clinical sleep research promises to lead to new and more targeted pharmacotherapy for sleep disorders. Thus, new drugs for therapeutic application in sleep disorder medicine arc clearly needed. For this purpose, objective assessments of drug effects with polysomnographic recordings, even in the very early phase of development in humans, are mandatory in Inhibitors,research,lifescience,medical a developmental plan for a new sleep-acting compound. In the present

paper, arguments for using sleep as a tool for the development of other drugs acting on the central http://www.selleckchem.com/products/CHIR-258.html nervous system (CNS) will be presented. In the following sections, we will discuss how the relationship between sleep physiology and neurotransmitter function could be used for the development of CNS-acting drugs. REM Inhibitors,research,lifescience,medical sleep pressure as a surrogate marker of a cognitive enhancer acting on cholinergic neurotransmission The cholinergic system is one of the most, important modulatory neurotransmitters in the brain and controls

many activities that depend on selective attention and conscious awareness. Drugs that antagonize muscarinic receptors induce hallucinations and reduce the level of consciousness, while Inhibitors,research,lifescience,medical the nicotinic receptor is implicated in the mode of action of general anesthetics.14 In degenerative diseases of the brain, such as Alzheimer’s disease, dementia with Lewy bodies, or Parkinson’s disease, alterations in consciousness, loss of memory, visual hallucinations, Inhibitors,research,lifescience,medical or rapid eye movement (REM) sleep abnormalities have been associated with regional deficits in the cholinergic system. In the following sections, we will briefly discuss the value of using REM sleep as a surrogate marker of compounds acting on cholinergic neurotransmission, and particularly in the development

of cognitive enhancers for Alzheimer’s disease. REM sleep REM Inhibitors,research,lifescience,medical sleep was first, described in 1953 by Aserinsky and Brefeldin_A Kleitman.15 At, regular 90- to 100-min intervals, they observed the spontaneous emergence of electroenccphalographic (EEG) desynchronization accompanied by clusters of rapid saccadic eye movements. When subjects were awakened during such an episode, they generally reported that they had been dreaming. REM sleep is also called paradoxical sleep because of the close resemblance to the EEG of active wakefulness combined with a “paradoxical” active inhibition of major muscle groups that, seems to reflect, deep sleep. Normal sleep is characterized in EEG terms as recurrent, cycles of nonREM and REM sleep of about, 90 min. Non -REM sleep is subdivided into stages 1 through 4, with stage 1 being the lightest and stage 4 being the deepest sleep.